On the stock market since 2018, it operates in the world of health and science. It has 74 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 54% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 68% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $25.9M a year. A small number, but proof the product has real buyers.
There is $910.1M in the vault; even if every debt were paid off, $419.1M would remain.
A loss of $129.5M against $25.9M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, ORXOY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ORXOY is a high-risk stock — not yet profitable, and its future rides on its product catching on.